Kiran Mazumdar-Shaw, the executive chairperson of Indian drugmaker Biocon Ltd., has expressed confidence that the company is on track to become the world's top supplier of insulin within the next five years. This ambition is driven by substantial investments and expanded production capacity, positioning Biocon to meet the increasing global demand for this critical drug. The company aims to fill a market gap as larger pharmaceutical firms redirect their focus towards newer metabolic medicines, such as GLP-1s, for diabetes and weight loss.
Biocon, currently the third-largest global insulin provider by volume, is strategically expanding its production capabilities to capitalize on this opportunity. Mazumdar-Shaw, often referred to as India's 'Queen of Biotech,' highlighted that the shift by major players like Novo Nordisk A/S and Eli Lilly & Co. creates a 'windfall' for Biocon, allowing them to scale up their insulin business significantly. The company is exploring partnerships worldwide to add capacity, including facilities for pens and cartridges.
While other pharmaceutical companies are intensely competing in the GLP-1 market, Mazumdar-Shaw noted that Biocon is taking a more measured approach. She views the generic GLP-1 market as 'crowded' with 'rock bottom' prices in India, stating that Biocon does not plan to sell its generic versions of semaglutide in its home country. Instead, Biocon intends to target select international markets for GLP-1s, such as Canada, Latin America, Brazil, the Middle East, and Southeast Asia, where opportunities are more favorable.
Biocon, founded by Mazumdar-Shaw almost 50 years ago, began as an industrial enzymes producer and has grown into a multibillion-dollar company with a market capitalization exceeding $7 billion. Mazumdar-Shaw's net worth, derived from stakes in Biocon, Syngene International Ltd., and Narayana Hrudayalaya Ltd., stands at $2.3 billion. Her vision extends to making life-saving drugs accessible and addressing critical health needs globally.
